u

Page 1 of 2 PCTUS1/REV03

•		AME.	ec'd PCT/PTO In 1	1 0	FD 190	Q	U9/	14207
	N NO. (IF KNOWN, SI		INTERNATIONAL APPLICA	MOIT		<del> </del>		DOCKET NUMBER
TO BE ASSIGNED PCT/GB97/00577			-		R-7450			
1	following fees are su NAL FEE (37 CFR		(5)) •			ŀ	CALCULATION	S PTO USE ONLY
	•	• • • • •	or JPO		\$930.0	0		
		•	id to USPTO (37 CFR 1.482)			ı		
☐ No interm	ational preliminary e	xamination fee	paid to USPTO (37 CFR 1.4	82)	\$720.00	"		
I			37 CFR 1.445(a)(2))		\$790.00	0		
internation	nal search fee (37 Cl	FR 1.445(a)(2)	n fee (37 CFR 1.482) nor paid to USPTO		\$1,070.00	)		
and all cl	aims satisfied provisi	ons of PCT Ar	ticle 33(2)-(4)		\$98.0	0		
			ATE BASIC FEE AN	JOL	J <b>NT</b> =		\$930.00	
	0.00 for furnishing the earliest claimed prior			20	□ 30		\$0.00	
CLAIMS	NUMBEI	R FILED	NUMBER EXTRA		RATE			
Total claims	14	- 20 =	0	x	\$22.00		\$0.00	
Independent clair		- 3=	0	x	\$82.00	_	\$0.00	
Multiple Depend	dent Claims (check i		A DOVE CALCIU		DIG.		\$0.00	
Peduction of 1/2			ABOVE CALCULA tble. Verified Small Entity S			-	\$930.00	
must also be file	ed (Note 37 CFR 1.9,	1.27, 1.28) <b>(cl</b>	neck if applicable).			]	\$0.00	
			SUI	вто	TAL =	=_	\$930.00	
Processing fee of months from the	\$130.00 for furnishi earliest claimed prior	ng the English rity date (37 C	translation later than $\Box$ FR 1.492 (f)).	20	□ 30	+	\$0.00	
			TOTAL NATIONA	LF	EE =	=	\$930.00	
Fee for recording accompanied by	the enclosed assignment appropriate cover	nent (37 CFR sheet (37 CFR	1.21(h)). The assignment mu 3.28, 3.31) (check if applications)	st be able).			\$0.00	
	7.3.90		TOTAL FEES ENC	LOS	ED :	=	\$930.00	
						ŀ	Amount to be: refunded	\$
							charged	\$
🛚 A check	in the amount of \$9	30.00	to cover the above fees is e	nclose	ed.			
	narge my Deposit Accate copy of this shee		in the amount	of			to cover the above	ve fees.
	one cop, or and should	o io onorosoa.						
▼ The Con	nmissioner is hereby	authorized to c	harge any fees which may be	requir	ed, or cred	lit ar	y overpayment	
to Depos	it Account No.	18-0350	A duplicate copy of this sheet	is end	closed.			
NOTE: Where 1.137(a) or (b))	an appropriate time must be filed and gr	e limit under 3 canted to resto	7 CFR 1.494 or 1.495 has n re the application to pendin	ot bee	en met, a p	etiti	on to revive (37 C	FR
	RESPONDENCE TO			9			The second	
Allan Ratner		1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		<u> </u>	GNATUR			
RATER & PR		`				3.2		
P.O. Box 980	Westlakes (Berwyn	,		<u>A</u>	llan Ratr	ıer		
	ennsylvania 19482	-0980		N.	AME			
United States of (610) 407-0700.			:	19	9,717			
(610) 407-0701	-			RI	EGISTRA	TION	NUMBER	<del> </del>
				01	1 Septem	ber	1998	
ĺ					ATE			

## 300 Rec'd PCT/PTO 01 SEP 1998

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Brian Burchell

: Art Unit:

Serial No.: TO BE ASSIGNED

: Examiner:

Filed:

HEREWITH

FOR: DRUG TRIAL ASSAY SYSTEM

#### PRELIMINARY AMENDMENT

**Assistant Commissioner for Patents** Washington, D.C. 20231

SIR:

Prior to examination of the above-identified application, please amend the above application as follows:

#### IN THE SPECIFICATION:

On page 1, before the title, please insert the following:

-- This application is the U.S. National Phase of PCT International Application No. PCT/GB97/00577.--.

#### IN THE CLAIMS:

Please amend the claims 3, 4, 5, 6, 7, 8, 10, 11, 12, and 14 as follows:

- Use of a test as claimed in claim 1 [or 2] wherein the sample 3. 1
- is chosen from blood, buccal smear or any other sample containing DNA from 2
- the potential participants.

1 2	4. Use of a test as claim in [any of the preceding] claim[s] $\underline{1}$ further comprising the step of eliminating participants having the genetic basis of
3	Gilbert's Syndrome from a drugs trial.
1	5. Use of a test as claimed in [any of] claim[s] 1 l[to 3]
2	wherein the method comprises the further step of selecting only participants
3	having genetic basis for Gilbert's Syndrome for a drugs trial.
1	6. Use of a test claimed in [any of] claim[s]s 1 [to 3] further
2	comprising the step of interpreting the results of the drugs trial in the knowledge
3	that certain participants have Gilbert's Syndrome.
1	7. Use of a test as claimed in [any of the preceding] claim[s] 1 wherein the method comprises the steps of:
2	
3	a) isolating DNA from each sample,
4	b) amplifying the DNA inner region indicating the genetic basis
5	for Gilbert's Syndrome,
6	c) isolating amplified DNA fragments, and
7	d) identifying individuals having the genetic basis of Gilbert's
8	Syndrome.
1	8. Use of a test as claimed in [any of the preceding] claim[s] 1
2	wherein the DNA is amplified using the polymerase chain reaction (PCR) using
3	a radioactively labeled pair of nucleotide primers.
1	10. Use of a test as claimed in [any of] claim[s] 7 [to 9] wherein
2	the DNA region indicating the genetic basis of Gilbert's Syndrome is the gene
3	encoding UDP-glucuronosyltransferase (UGT).
1	11. Use of a test as claimed in [any of] claim[s] 7 [to 10]
2	wherein the DNA to be amplified is in an upstream promoter region of the UGT
3	1*1 exon 1.
1	12. Use of a test as claimed in [any of] claim[s] 7 [to 11]
2	wherein the DNA to be amplified includes the regions between -35 and -55

nucleotides at the 5' end of UGT 1\*1 exon.

1	14. Primers for use of a test as claimed in [any of the preceding]
2	claim[s] 1 including primer pairs, AB or CD as follows:
3	A/B(1,5' -AAGTGAACTCCCTGCTACCTT-3',
4	B,5' -CCACTGGGATCAACAGTATCT-3') or
5	C/D (C,5'-GTCACGTGACACAGTCAAAC-3';
6	D 5' -TTTGCTCCTGCCAGAGGTT-3').

Respectfully Submitted,

Allan Ratner, Reg. No. 19,717 Attorney for Applicant

AR:sls

Dated: September 1, 1998

Suite 301 One Westlakes, Berwyn P.O. Box 980 Valley Forge, PA 19482-0980 (610) 407-0700

The Assistant Commissioner for Patents is hereby authorized to charge payment to Deposit Account No. 18-0350 of any fees associated with this communication.

EXPRESS MAIL Mailing Label Number: EL 013 897 799 US Date of Deposit: September 1, 1998

I hereby certify that this paper and fee are being deposited, under 37 C.F.R. § 1.10 and with sufficient postage, using the "Express Mail Post Office to Addressee" service of the United States Postal Service on the date indicated above and that the deposit is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, Attn: Box PCT (RO/US)

Jan Landis

09/142095

WO 97/32042

PCT/GB97/00577

300 Rec'd PCT/PTO 01 SEP 1998

"Drug Trial Assay System"

3

413

1 2

> The present invention relates to drug trials, usually carried out for or on behalf of pharmaceutical

1

4

companies. More particularly the invention relates to 5

a method for improving the efficacy of drug trials. 6

7

In the different stages of drug trials, regulatory 8

authorities in different European countries and the FDA 9

in the USA require extensive data to be provided in 10

order to approve use of the drugs. 11

12

It is important that as much information as possible is 13

available in relation to all participants who take part 14

in drug trials, from volunteers who take part in phase 15

1 trials to patients involved in stage 3 clinical 16

trials. 17

18

In particular, if certain individuals or groups of 19

individuals have severe or abnormal reactions to drug 20

administration, further studies involving that drug 21

will be in jeopardy unless the reason for the reaction 22

is realised. 23

24

The knowledge of pharmacogenetics can play an important 25

#### PCT/GB97/00577

1 role in understanding the impact of drug metabolism on 2 pharmacokinetics, role of receptor variants in drug response and in the selection of patient populations 3 for clinical studies. 4

5 6

7

8

9

10

11

Considerable effort has been expended in attempting to identify the pharmacogenetic basis of idiosyncratic adverse drug reactions, particularly hypersensitivity While there is clear evidence for reactions. pharmacogenetic influence on susceptibility to hypersensitivity reactions, necessary and sufficient pharamacogenetic defects have not been identified.

12 13 14

15

16

### ### 1.13

82

ģ. . . i=

į.i.i.

Marie Marie

The clinical implications of genetic polymorphism in drug metabolism have been studied extensively (See Tucker GT (1994) Journal Pharamacology 46 pages 417-424).

17 18 19

20

21

22

23

24 25

26 27

28

29

30

31

32

33 34

35 36 Gilbert's Syndrome (GS) is a benign unconjugated hyperbilirubinaemia occurring in the absence of structural liver disease and overt haemolysis and characterized by episodes of mild intermittent It is part of a spectrum of familial unconjugated hyperbilirubinaemias including the more severe Crigler-Najjar (CN) syndromes (types 1 and 2). GS is the most common inherited disorder of hepatic bilirubin metabolism occurring in 2-12% of the population and is often detected in adulthood through routine screening blood tests or the fasting associated with surgery/intercurrent illness which unmasks the hyperbilirubinaemia13. The most consistent feature in GS is a deficiency in bilirubin glucuronidation but altered metabolism of drugs has also been reported3-5. Altered rates of bilirubin production, hepatic haem production and altered hepatic uptake of bilirubin have been reported in some GS patients2.

> RECTIFIED SHEET (RULE 91) ISA/EP

- Due to the benign nature of the syndrome and its 1
- 2 prevalence in the population it may be more appropriate
- to consider GS as a normal genetic variant exhibiting a 3
- 4 reduced bilirubin glucuronidation capacity (which in
- 5 certain situations such as fasting, illness or
- 6 administration of drugs) could precipitate jaundice.

- 8 In drug trials where high levels of serum total
- 9 bilirubin is detected for certain individuals, it is
- not clear whether this is because the individuals have 10
- Gilbert's Syndrome or if it because of an effect of the 11
- drug. Whereas presently, results are explained merely 12
- 13 by saying that the individuals have Gilbert's Syndrome,
- 14 it is suspected that in the future, it will be
- 15 necessary to prove this fact.

16

- 17 Where a jaundiced phenotype is apparent after
- 18 volunteers have been accepted for a trial and have been
- 19 subjected to five days of a strict diet, no alcohol and
- 20 no smoking, the jaundiced appearance giving an
- 21 indication that the individuals have Gilbert's
- 22 Syndrome, may cause them to be ruled out of the trial?
- 23 Therefore, where approximately 250 individuals would be
- required for phase 1 trials and about 6000 patients for 24
- 25 phase 3 trials, unnecessary time and effort would have
- 26 been spent during the first 5 days of these trials and
- 27 individuals having Gilbert's Syndrome may be ill
- 28 effected.

29

- 30 Bosma et al. (New England Journal of Medicine (1995)
- 31 volume 333 Number 18) reported the genetic basis of
- 32 Gilbert's syndrome.

33

- 34 The present invention aims to provide a method of
- 35 improving the efficacy of drug trials in view of the
- 36 problems mentioned above.

6104070701;#43

3a

- According to the present invention there is provided a 1
- method for improving the efficacy of drug trials, the 2
- method comprising the step of screening samples from 3

PCT/GB97/00577 WO 97/32042

MURGITROYD & CO.→

individuals for the genetic basis of Gilbert's 1 Syndrome. 2 3 In a prefered embodiment of the invention the method 4 comprises the steps taking a sample from each potential 5 participant in a drug trial, screeing the samples for 6 the genetic basis of Gilbert's Syndrome, identifying 7 participants having the genetic basis of Gilbert's 8 9 Syndrome. 10 The sample may comprise blood, a buccal smear or any 11 other sample containing DNA from the individual to be 12 13 tested. 14 In one embodiment the method comprises the further step 15 of eliminating participants having the genetic basis of 16 Gilbert's Syndrome from the drug trial. 17 18 In an alternative embodiment, the method can comprise 19 the further step of selecting participants having the 20 genetic basis of Gilbert's syndrome and eliminating 21 others from the drug trial. 22 23 In a further alternative the results of the drug trials 24 can be interpreted in the knowledge that certain 25 participants have Gilbert's Syndrome. 26 27 Preferably the method comprises the steps of isolating 28 DNA from each sample, amplifying the DNA in a region 29 indicating the genetic basis of Gilbert's Syndrome, 30 isolating amplified DNA fragments by gel 31 electrophoresis and identifying individuals having the 32 genetic basis of Gilbert's disease. 33

34

Preferably the DNA is amplified using the polymerase 35 chain reaction (PCR) using a radioactively labelled 36

į...į.

IJ

413

36

WO 97/32042

PCT/GB97/00577

6104070701;# 8

5

```
1
      pair of nucleotide primers.
 2
      The primers are designed to prime the amplification
 3
      reaction at either side of an area of the genome known
 4
 5
      to be associated with Gilbert's Syndrome.
 б
 7
 8
      Preferably the DNA region indicating the genetic basis
      of Gilbert's Syndrome is the gene encoding UDP-
 9
10
     'qlucuronosyltransferase (UGT).
11
      By gene is meant, the non coding and coding regions and
12
13
      the upstream and downstream noncoding regions.
14
      In a preferred embodiment the DNA to be amplified is in
15
16
      an upstream promoter region of the UGT1*1 exon1.
17
      Most preferably the DNA to be amplified includes the
18
19
      region between -35 and -55 nucleotides at the 5' end of
20
      UGT1*1 exon.
21
      According to the invention there are provided suitable
22
      primers for use in a PCR reaction including primer
23
24
      pairs;
25
      A/B(A,5'-AAGTGAACTCCCTGCTACCTT-3',
26
      B,5'-CCACTGGGATCAACAGTATCT-3') or
27
      C/D (C,5'-GTCACGTGACACAGTCAAAC-3';
28
      D 5'-TTTGCTCCTGCCAGAGGTT-3')
29
30
      The invention further comprises a kit for screeking
31
      individuals for participation in drug trials, the kit
32
      comprising primers for amplifying DNA in a region of
33
      the genome indicating the genetic basis of Gilbert's
34
35
      Syndrome.
```

**RECTIFIED SHEET (RULE 91)** ISA/EP

PCT/G/B97/00577

		6
1	Usin	g primer sequences as described herein, DNA can be
2	ampl	ified and analysed using among others any of the
3	foll	owing protocols;
4		
5	Prot	ocol   Radioactive method
6		
7	1.	Extract DNA from Buccal Cells or 3ml Blood.
8		
9		
10	2.	Choose primers from either side of the "TATA" box
11		region of UGT1*1 exon1 regulatory sequence.
12		Freshly end label one primer with $[\gamma^{32}\alpha]$ -ATP (40
13		min).
14		·
15	3.	Amplifying a small region up to 100 bp in length
16		by PCR (2h).
17		
18	4.	Apply to 6% PAG denaturing gel (preparation,
19		loading, run time, 4h).
20		
21	5.	Expose (-70°C) wet gel to autoradiographic film
22		(15 min).
23		
24		method takes about 7h to complete. Polymorphisms
25	only	observed in TATA box non coding region todate.
26		
27	Prot	ocol 2
28	Alte	rnative Radioactive Method: Solid Phase
29	Minis	sequencing
30		
31	1 _	Extract DNA (as above)

31

32

Prepare primers biotinylating one 33 2.

34

Amplify DNA by PCR using primers 35 3.

36

WO 97/32042

PCT/GB97/00577

7

Captive biotinylated PCR products on streptavidin 4. coated support and deactive.

Carry out primer extension reaction sequencing. 5.

5

6 Protocol 3

7 Non-Radioactive Methods:

8

- (a) Analysis by Single Strand Conformational 9 Polymorphism (SSCP) 10
- 11 ı. Extract DNA (as above).

12

Choose primers either side of the TATA Box. 13 2.

14

412

the Hall was he will

Į...L

ğ=::±

The State of the S

- Amplify a small region up to 100 bp in length by 15 з. PCR (2H). 16
- 17 4. Denature and place on ice (15 min).

18

5. Load onto a non-denaturing PAG gel, 19 (preparation/load/run time, 4h). 20

21

Stain with Ethidium bromide or silver nitrate (30 22 6. mm).

23 24

- This method still takes about 7h to complete, but is 25
- potentially slightly cheaper since there is no 26
- radioactivity or autoradiography. 27

28

- This method could be done on an automated DNA sequencer 29
- from stage 5, if primers are tagged with chromophores 30
- in PCR stages 2 and 3. Result would then be read 31
- 32 automatically.

33

34 Oligonucleotide Assay Hybridization

35

36 1. Extract DNA (as above).

, 111

WO 97/32042

PCT/GB97/00577

8

Choose primers and amplify DNA by PCR up to 100 bp
 in length.

3 4

3. Apply DNA to plastic grids.

5

6 4. Screen bound DNA samples with specific DNA probes
7 for TA<sub>5</sub>, TA<sub>6</sub>, TA<sub>7</sub> tagged with different
8 coloured/fluorescent chromphores.

9

10 5. Read ouput automatically for experimental protocols.

12

13 References

14

15 Monaghan G et al. Lancet (1996) 347 578-581.

16

- "Detection of polymorphisms of human DNA by gel electrophoresis or single-strand conformational
- 19 polymorphisms"." Orita M et al. Proc Matl Acad Sci
- 20 (USA) (1989) 86 2766-2700.

21

- 22 "Assays of complementary oligonucleotides for analysing
- 23 Hybridization behaviour of Nucleic Acids". Southern E
- 24 M. Nuc Acids Res (1194) 22 1368-1373.

36

WO 97/32042 PCT/GB97/00577

9

The basis of the invention is illustrated in the 1 following example with reference to the accompanying 2 figures wherein: 3 5 Figure 1 illustrates genotypes at the TATA box sequence 6 upstream of the UGT1\*1 exon 1 determined by direct 7 sequencing and radioactive PCR. 8 9 Figure 2 illustrates serum total bilirubin (μmol/1) 10 plotted against UGT1\*1 exon 1 genotype. 11 Figure 3 illustrates segregation of the 7/7 genotype 12 13 with elevated serum total bilirubin concentration in a family with GS. 14 15 Figure 4 illustrates the 5' sequence of the UGT1\*1 exon 16 17 1 and the position of the primers with respect to the 18 UGT gene. 19 20 Example 21 22 We have examined the variation in the serum total bilirubin (STB) concentration in a representative group 23 24 of the Eastern Scottish population (drug-free, alcohol-25 free non-smokers) in relation to genotype at the UDP-26 glucuronosyltransferase subfamily 1 (UGT1) locus. 27 Subjects with the 77/7 genotype in this population have a significantly higher STB than those with 6/7 or 6/6 28 29 genotypes. Of 14 control subjects who underwent a 24 30 hour fast to establish whether they had Gilbert Syndrome (GS), only 7/77 subjects had GS. In addition, 31 one confirmed GS patient, two recurrent jaundice 32 patients and 9 clinically diagnosed GS patients had the 33 7/7 genotype. Segregation of the 7/7 genotype with 34

elevated STB concentration has also been demonstrated in a family of 4 Gilbert members. This incidence of

PCT/GB97/00577

10

the 7/7 genotype in the population is 10-13%. Here, we 1 demonstrate a correlation between variation in the 2 human STB concentration and genotype at a TATA sequence 3 upstream of the UGT1\*1 exon 1 and that the 7/7 genotype 4 is diagnostic for GS. 5 б The inheritance of GS has been described as autosomal 7 dominant or autosomal dominant with incomplete 8 penetrance based on biochemical analysis. More recent 9 reports have suggested that the mildly affected 10 (Gilbert) members of families in which CN type 2 (CN-2) 11 occurs are heterozygous for mutations in the UDE 12 glucuronosyltransferase subfamily 1 (UGT1) gene which 13 cause CN-2 in the homozygous state. The inheritance of 14 GS in these families is autosomal dominant while CN-2 15 is autosomal recessive 7-11. However, the incidence of 16 rare and the frequency CN-2 in the population is 17 of alleles causing CN-2 would not be sufficient to 18 explain the population incidence of GS. 19 20 An abstract by Bosma et al12 suggested a correlation 21 between homozygosity for a 2bp insertion in the TATA 22 box upstream of UGT1\*1 exon 1 and GS (no mutations were 23 found in the coding sequence of the UGT1\*1 gene). In 24 this report we demonstrate that the primary genetic 25 factor contributing to the variation in the serum total 26 bilirubin (STB) concentration in the Eastern Scottish 27 population is the sequence variation reported by Bosma 28 et al<sup>12</sup>. In addition, we show that the 7/7 genotype --29 associated with GS and occurs in 10-13% of the 30 population. 31 32 Methods 33 Patients and Controls 34 Whole blood (3ml) was collected into EDTA(K3) 35 Vacutainer tubes (Becton Dickinson) from one confirmed 36

£.

Ü

Į...i.

= := = :=

P.J £112

1,2

Į..L 1...

£.J

Ŋ

ij.

ű

34 35

36

#### PCT/GB97/00577

11

male Gilbert patient (diagnosed following a 48 hour 1 restricted diet(3), two female patients with recurrent 2 jaundice/associated elevated STB (29-42 μmol/1) and 9 3 4 (1 female, 8 male) clinically diagnosed GS subjects 5 (persistent elevation of the STB amidst normal liver 6 function tests.) The patients were aged 22-45 years. 7 8 77 non-smoking residents selected at random from the Tayside/Fife region of Scotland (39 females aged 19-58 9 10 years, mean 32.41± 10.94; 38 males aged 23-57, means 35.58  $\pm$  9.04) participated in this study. Whole blood 11 (9ml) was collected 8-10am) into EDTA(K3) Vacutainer 12 tubes (Becton Dickinson) for DNA extraction and SST 13 Vacutainer tubes (Becton Dickinson) for biochemical 14 15 investigations. The subjects had not taken any medication or alcohol in the previous 5-7 days and had 16 17 fasted overnight (12 hours). 14 controls subsequently underwent further biochemical tests (following a 3 day 18 abstinence from alcohol) before and after a 24 hour 19 400-calorie dieti4 to determine if they had GS. All 20 patients/controls were fully informed of the study and 21 22 gave consent for their blood to be used in this study. 23 24 Biochemistry and DNA Extraction 25 26 The following biochemical tests were performed on 27 control blood samples; alanine aminostransferase, 28 albumin, alkaline phosphatase, amylase, STB, 29 cholesterol, creatinine, creatine kinase, free thyroxine, gamma-glutamyl-transferase, glucose, HDL-30 31 cholesterol, HDL-cholesterol/total cholesterol, iron, 32 lactate dehydrogenase, percentage of saturated 33 transferrin (PSAT), proteins, serum angiotensin

converting enzyme, thyroid stimulating hormone,

also had pre- and post-fasting (24 hour) alanine

transferrin, triglycerides, urate, urea. 14 controls

WQ 97/32042

PCT/GB97/00577

12

aminostransferase, albumin, alkaline phosphatase, STB 1 and urate measured. DNA was prepared using the Nucleon 2 II Genomic DNA Extraction Kit (Scotlab) according to 3 manufacturer's instructions. 4 5 Genotyping 6 7 Polymerase Chain Reaction 8 9 Primer pairs A/B (A, 5'-AAGTGAACTCCCTGCTACCTT-3'; B, 10 5'-CCACTGGGATCAACAGTATCT-3') or C/D (C,5'-11 GTCACGTGACACAGTCAAAC-3';D, 5'-TTTGCTCCTGCCAGAGGTT-3') 12 flanking the TATA box sequence upstream of the UGT[\*1 1 \* 113 exon 1 were used to amplify fragments of 253-255bp and 14 98-100bp, respectively. Amplifications (50 $\mu$ l) were 15 performed in 0.2mM of each deoxynucleoside triphosphate 16 (datp, dctp, dgtp, dttp), 50mM KCI, 10mM Tris.HCl (pH 17 9.0 at 25 C), 0.1% Triton X-100, 1.5mM MgCl<sub>2</sub>, 0.25μM of 18 each primer, 1 Unit of Taq Polymerase (Promega) and 19 human DNA  $(0.25-0.5\mu g)$ . The polymerase chain reaction 20 (PCR) conditions using the Perkin-Elmer Cetus DNA 21 Thermal Cycler were: 95'C 5 min followed by 30 cycles 22 of 95° 30 sec, 58°C 40 sec, 72°C40 sec. 23 24 Direct Sequencing 25 26 Amplification was confirmed prior to direct sequencing 27 by agarose gel electrophoresis. Sequencing was 28 performed using  $\{\alpha^{-35}S\}$ -dATP (NEN Dupont) with the USB 29 Sequenase PCR Product Sequencing Kit according to 30 manufacturer's instructions. Sequenced products were 31 resolved on 6% denaturing polyacrylamide gels. The 32 dried gels were exposed overnight to autoradiographic 33 film prior to developing. 34 35

Radioactive PCR 36

1.7

ŲŽ

. Suis

ļ...i.

N

ij ij

34

35

36

WQ 97/32042

PCT/GB97/00577

13

1 Amplification was performed as above using primer pair C/D except that 2.5 pmol of primer C was radioactively 2 5' end-labelled with 2.5 $\mu$ Ci of  $(\gamma^{-12}P)$ -ATP (NEN Dupont) 3 prior to amplification. Products were resolved on 6% 4 denaturing polyacrylamide gels and the wet gels exposed 5 to autoradiographic film (-70°C 15 min) and the 6 autoradiographs developed. 7 8 9 Statistics 10 A t-test was used to determine if there was a 11 significant age difference between males and females. 12  $\chi^2$  analysis was used to assess any difference in the 13 14 distribution of the 6/6, 6/7 and 7/7 genotypes in males and females and also to determine if the 7/7 subjects 15 from the 24 hour fasted group had STB elevated into the 16 range diagnostic for GS14. An analysis of variance was 17 performed to compare mean STB in males and females 18 19 within each genotype group. A non-parametric test, the Mann-Whitney U-Wilcoxon Rank Sum W Test was used to 20 determine whether there was a significant difference in 21 22 mean STB between males and females (irrespective of genotype). Correlations and significance tests were 23 24 performed for STB versus PSAT and STB versus iron. A 25 probability (p) of ( 0.05 was accepted as significant. 26 27 Results 28 In Figure 1 a photographic representation of the sense 29 30 DNA sequences obtained by PCR/direct sequencing of DNA samples having the genotypes 6/6, 6/7 and 7/7 is shown. 31 32 The common allele, (TA), TAA, is denoted by "5" while the rarer allele, (TA), TAA, is denoted by "7". Below each 33

sequence is an overexposed photographic representation of the 98 to 100bp resolved fragments amplified using

primer pair C/D which flank the TATA sequence upstream

```
of the UGT1*1 exon 1. The additional fragments of 99
1
      and 101 bases are thought to be artifacts of the PCR
 2
      process where there is non specified addition of an
 3
      extra nucleotide to the 3' end of the amplified
 4
      product21. | Figures 1b illustrates results after testing
5
      a range of unknown individuals.
 6
 7
      In Figure 2 males (M) and females (F) are plotted
 8
      separately | Each circle/square represents the result
9
      of a single control subject. The squares indicate the
10
      14 controls who also underwent the 24 hour restricted
11
      diet (see Methods). The filled circles/squares
12
      represent those who had a lower than normal PSAT (≤
13
      22%) while the half-tone circles represent those who
14
      had a higher than normal PSAT (≥ 55%). The mean STB
15
      concentrations (indicated by the horizontal lines) for
16
      males were 13.24 \pm 3.88 (6/6), 13.94 \pm 6.1 (6/7)
17
      including control h or 12.69 ± 3.34 excluding control
18
      h, 29 \pm 14 45 (7/7) and for females were 9 \pm 3.62
19
      (6/6), 12.2 \pm 3.53 (6/7), 21.6 \pm 7.8 (7/7). The
20
      encircled result is from control h (discussed in the
21
      text).
22
23
      In Figure 3 males and females are represented by
24
      squares and circles, respectively. Filled and half-
25
      filled circles/squares indicate the genotypes 7/7 and
26
      6/7, respectively. The numbers in parentheses below
27
      each member of the pedigree are the STB concentrations
28
      measured after a 15 hour fast and 7 day abstinence from
29
      alcohol. All family members were non smokers who were
30
      not taking any medication when the biochemical tests
31
      were performed. Elevated STB are underlined.
32
      Individual members of each generation (I or II) are
33
      denoted by the numbers 1-4 above each circle/square.
34
```

7.J

ŧij.

u

į...<u>i.</u>

ĦĴ

ŧij.

Ēij.

Generation III have not yet been tested.

1.3 ij.

ij.

ā.,;

ğu. 711<u>1</u>

Ţij,

ijŢ

£Ü.

36

PCT/GB97/00577

15

There was no significant age difference between males 1 2 and females (t = -1.38, p = 0.17). Genotypes were determined initially by amplification/sequencing and 3 later by the radioactive PCR approach. Individuals 4 5 homozygous for the common allele, hetrozygous or homozygous for the rarer allele have the genotypes 6/6, 6 7 6/7 and 7/7, respective. 12 DNA samples (2 of 6/6, 3 8 of 6/7 and 4 of 7/7) were analysed by both methods and 9 genotype results were identical (see Figure 1). 10 Genotype frequencies in male controls were 6/6 (44.74%, 11 6/7 (44.74%), 7/7 (10.52%) and in female controls were 12 13 6/6 (35.9%), 6/7 (51.3%), 7/7 (12.8%). There was no significant difference between the genotype proportions 14 in the two groups ( $\chi^2 = 0.6$  at 2 df, p = 0.7). Control 15 h (encircled in Figure 2) had a STB which was 2.4 SD 16 above the mean STB for that group (mean calculated 17 including control h). The results for control h were 18 repeatable and he is currently being investigated to 19 exclude haemochromatosis. Comparison of mean STB in 20 males and females revealed that females have a 21 significantly lower concentration than males (p = 0.03122 including control h; p + 0.0458 excluding control h). 23 24 There was a strong correlation between genotype and mean STB concentration within the control group (p ( 25 0.001) irrespective of whether control h was included 26 and there was a significant difference in mean STB 27 28 between males and females of the same genotype (p ( 29 0.05) irrespective of whether control h was included (see Figure 2). All patients studied had the 7/7 30 31 genotype. 32 Correlations between STB/PSAT (r = 0.4113, p = 33 0.001) (see Figure 2) and STB/iron females (p = 0.001) 34 than males (p = 0.01) but when control h is excluded 35 there was no significant correlation in males.

#### PCT/GB97/00577

16

1	The STB concentrations of control who underwent the 24
2	hour restricted diet (see Methods) are shown in Tatio
3	1. The normal fasting response is a small rise in the
4	base-line STB (not exceeding a final concentration of
5	25μmol/1) most of which is unconjugated while GS
6	patients have a lone biochemical feature a raised STB
7	()25 $\mu$ mol/1 but (50 $\mu$ mol/1) most of which is
8	unconjugated4. The 6/6 and 6/7 controls had post-
9	fasting STB of ≤23μmol/1 while all 7/7 controls were
10	≥31µmo1/1. Other liver function tests were within
11	acceptable ranges for the age and sex of the subjects.
12	The 7/7 genotype correlates with a fasted STB (24
13	hour) within the range diagnostic for GSM (p (
<b>L</b> 4	0.01) (see Table 1). In addition, the 7/7 genotype
15	segregates with elevated STB concentration in a family
16	with 4 GS members (Figures 3).
17	
18	Table 1 shows a comparison of the UGT1*1 exon 1
19	genotype with elevation in the serum total bilirubin
20	after a 24 hour 400-calorie restricted diet 4.
21	•
22	An elevation of the fasting STB to a final
23	concentration in the range 25-50 mmol/l is considered to
24	be diagnostic for GS14. The 7/7 subject denoted by *
25	has a fasting and non-fasting STB of > 50 mmol/l but
26	this value is within a range considered by others to

conform to a diagnosis of GS7-11.

27

PCT/GB97/00577

17

Table 1

		24 hou	r fast	
Genotype	Sex	Before	After	Fasting bilirubin >25 & <50µmol/l
6/6	M M M	8 9 12	17 19 15	NO NO NO
6/7	F F F M M	8 9 11 12 8 15	17 13 12 17 10 23 18	NO NO NO NO NO NO
7/7	F F M M	9 12 19 62	34 34 31 96	Yes Yes Yes No*

Discussion

1 2 3

4

5

6

7

8

9

10

A few recent reports claim to have identified the genetic cause of GS10-12. Clinical diagnosis of GS is often based on a consistent midly elevated non-fasting STB ()17  $\mu$ mol/1) as the sole abnormal liver function test, intermittent jaundice or both. The diagnosis can be confirmed by elevation of the STB to  $25-50\mu\text{mol/1}$ after a 24 hour 400-calorie diet14 or by elevation of the unconjugated bilirubin by ) 90% within 48 hours of commencing a 400 calorie diet13.

11 12 13

14

15

16

17

18

Sato's research group recently reported the occurrence of 7 different heteroxygous missence mutations in unrelated Gilbert patients (most of the mutations have been found in the homozygous state in affected members of CN families), however, the non-fasted STB for thepatients were  $\rangle$  52 $\mu$ mol/1 (with the exception of one,

36

18

1	31μmol/1) 10.12. These non-fasted STB concentrations
2	already exceed the diagnostic range for GS14, hence
3	these patients have a more severe form of
4	hyperbilirubinaemia than those studied in this report,
5	while those in the Bosma et al 12 abstract had STB
6	concentrations similar to those studied here.
7	
8	The example herein shows that the variation in the
9	levels after an overnight fast (and in the absence of
10	exposure to known inducers of the UGT1*1 isoform in GS,
11	such as alcohol 15 and drugs16) a representative group
12	of the Eastern Scottish population is primarily due to
13	(or associated with) the TATA box sequence variation
14	reported by Bosma et al <sup>12</sup> . In agreement with previous
15	work females have a significantly lower mean STB
16	concentration than males 17-18.
17	
18	Individuals with the 7/7 genotype in the population
19	have GS (see Table 1). One of the 7/7 controls
20	indicated in Table 1 had a non-fasting STB similar to
21	those reported for heterozygous carriers of CN-2
22	mutations 7-4 which suggests that this subject may also
23	be a carrier of a CN-2 mutation, alternatively, the
24	very elevated bilirubin in this patient may be due to
25	the coexistence of Reavon's Syndrome (characterized by
26	a collection of abnormal biochemical results which are
27	risk factors for coronary heart disease) 19.
28	
29	We have found that 10-13% of the Eastern Scottish
30	population have the genotype associated with mild GS.
31	None of the Gilbert subjects from the control
32	population were aware that they had an underlying
33	metabolic defect in glucuronidation with testifies to
34	its benign nature. Three 7/7 controls had STB
35	concentrations comparable to mean levels observed in

heterozygotes, however, they also had a lower than

PCT/GB97/00577

19

1 normal PSAT (≤22%) (see Figure 2). The observed 2 correlation between STB and PSAT (p = 0.001) (Figure 2) 3 and STB and iron (females p = 0.001 and males p = 0.01including control h) indicates that other genetic and 4 5 environmental factors affecting the serum PSAT and iron 6 values will in turn affect the STB concentration. 7 8 From the data presented here and previous reports it 9 seems clear that there are mild and more severe forms 10 The milder form (fasted STB 25-50µmol/1) is 11 either caused by (or is associated with) a homozygous 12 2bp insertion at the TATA sequence upstream of the 13 UGT1\*1 exon 1 (autosomal recessive inheritance) while the rarer more severe dominantly inherited forms 14 identified to date7-11 (non-fasted STB ) 50 mmol/1 are due 15 16 to heterozygosity for a mutation in the coding region 17 of the UGT1\*1 gene which in its homozygous state causes 18 CN-2. The particular genetic abnormality causing GS in 19 a patient will have implications for genetic 20 counselling as the dominantly inherited form of two GS 21 patients could result in offspring with CN-2, whereas 22 the recessive form in one or both GS patients would 23 have less serious implications. It is important to 24 discriminate between the two forms and provide suitable 25 genetic counselling for such couples. The rapid DNA 26 test presented here (less than 1 day for extracted DNA) 27 carried out in addition to biochemical tests following 28 a 12 hour overnight fast (without prior alcohol or drug 29 intake would permit such a diagnosis. The compliance rate for the current 24 and 48 hour restricted diet 30 tests for GSB-16 is debatable and hence the overnight 31 32 fast has obvious advantages and only one blood sample 33 or a buccal smear is required (for genetic and 34 biochemical analysis) in contrast to the 2-3 blood 35 samplings required for the 24 and 48 hour tests. This 36 approach to GS testing would be cost effective in terms

ij ij fi,j ţ.,ĵ Ē.,L å.,<u>b</u> Ŧij. ij 0j

đij.

WO 97/32042

#### PCT/GB97/00577

20

of fewer patient return visits to clinics and in 1 identifying couples at risk of having children with 2 CN-2. 3 4 In addition, the recent finding of an increased 5 bioactivation of acetominophen (a commonly used 6 analgesic which is eliminated primarily by 7 glucuronidation) in GS patients indicates the greater 8 potential for drug toxicity in these patients if 9 administered drugs which are also conjugated by UGT1 10 isoforms<sup>3</sup>. In fact, ethinylestradiol (EE2) has recently 11 been shown to be primarily glucuronidated by the UGL- - 1 12 isoform in man and hence this could have implications 13 for female Gilbert patients taking the oral 14 contraceptive who are then more predisposed to 15 developing jaundice. 16 17 18 The tests outlined herein have obvious implications for 19 setting up drug trials in understanding unusual results 20 in ruling out individuals who may be adversely affected 21 by the drugs or in positively choosing these 22 individuals to determine the effects of particular 23

drugs on hyperbilirubinaemia.

24 25

PCT/GB97/00577

21

1 References 2 3 Fevery, J. Pathogenesis of Gilbert Syndrome. Eur. 1 J. Clin. Invest. 1981;11; 417-418. 4 5 Watson, K.J.R. and Gollan, J.L. Gilbert's 2. 6 Syndrome. Bailliere's Clinical Gastroenterology 7 1989; 3: 337-355. 8 9 De Morais, S.M.F., Uetrecht, J.P. and Wells, P.G. 3. 10 Decreased glucuronidation and increased 11 bioactivation of acetaminophen in Gilbert's 12 Syndrome. Gastroenterology 1992; 102: 577-586. 13 14 Carulli, N., Ponz de Leon, M., Mauro, E., Manenti, 4. 15 F and Ferrari, A. Alteration of drug metabolism in 16 Gilbert's Syndrome. Gut 1976; 17: 581-587. 17 18 5. Macklon, A.F., Savage, R.L. and Rawlins, M.D. 19 Gilbert Syndrome and drug metabolism. Clin. 20 Pharmacokinetics 1979; 4: 223-232. 21 22 6. Thompson, R.PH.H. Genetic transmission of 23 Gilbert's Syndrome in "Familial 24 Hyperbilirubinaemia", (Ed. L. Okoliosanyi), John 25 26 Wiley & Sons Ltd; 91-97. 27 Gollan, J.L. Huang, S.N., Billing, B. and 28 7. Sherlock, S. Prolonged survival in three brothers 29 with severe type 2 Crigler-Najjar Syndrome. 30 Gastroenterology 1975; 68: 1543-1555. 31 32 Moghrabi, N., Clarke, D.J., Boxer, M. and 8.

33 8. Moghrabi, N., Clarke, D.J., Boxer, M. and
34 Burchell, B. Identification of an A-to-G missence
35 mutation in exon 2 of the UGT1 gene complex that
36 causes Crigler-Najjar Syndrome type 2. Genomics

with the three three three three

WO 97/32042

PCT/GB97/00577

		22
1		1993; 18: 171-173.
2		
3	9.	Moghrabi, N.N. Molecular Genetic Analysis of the
4		Human Phenol and Bilirubin UDP-
5		Glucuronosyltransferase Gene Complex and
6		Associated Disease Syndromes. PhD thesis 1994,
7		University of Dundee, Dundee, Scotland.
8		
9	10.	Aono, S., Adachi, Y., Uyama, E., Yamada, Y.,
10		Keino, H., Nanno, T., Koiwai, O. and Sato, H.
11		Analysis of genes for bilirubin UDP-
12		glucuronosyltransferase in Gilbert's Syndrome,
13		Lancet 1995; 345: 958-959.
14		
15	11.	Koiwai, O., Nishizawa, M., Hasada, K., Aono, S.,
16		Adachi, Y., Mamiya, N. and Sato, H. Koiwai, O.,
17		Nishizawa, M., Hasada, K., Aono, S., Adachi, Y.,
18		Mamiya, N. and Sato, H. Gilbert's Syndrome is
19		caused by a heterozygous missence mutation in the
20		gene for bilirubin UDP-glucuronosyltransferase.
21		Hum. Molec. Genet. 1995; 4: 1183-1186.
22		
23	12.	Bosma, P., Goldhoorn, B., Bakker, C., Out, T., Roy
24		Chowdhury, J., Roy Chowdhury, N., Oostra, B.,
25		Lindhout, D., Michiels, J., Jansen, P., Tytgat, G.
26		and Oude Elferink, R. Presence of an additional TA
27		in the TATAA box of B- UGT1 correlates with
28		Gilbert Syndrome. Hepatology October 1994;
29		Abstract 680: 226A.
30		
31	13.	Owens, D. and Sherlock, S. Diagnosis of Gilbert's
32		Syndrome: role of reduced calorie intake test.

Br. Med.J. 1973; 3: 559~563. 33

34

14. Lascelles, P.T. and Donaldson, D. Calorie 35 restriction test in "Diagnostic Function Tests in 36

253.

WO 97/32042

#### PCT/GB97/00577

23 Chemical Pathology" Kluwer Academic Publishers 1 2 1989: 24-25. 3 Ideo, G., De Franchis, R., Del Ninno, E. and 4 15. Dioguardi, N. Ethanol increases liver uridine-5 diphosphate-glucuronosyltransferase. Experientia 6 1971; 27: 24-25. 7 8 Sutherland, L.T., Ebner, T. and Burchell, B. 9 Expression of UDP-Glucuronosyltransferases (UGT) 1 10 family in human liver and kidney. Biochem. 11 Pharmacol. 1993; 45: 295-301. 12 13 17. Owens, D. and Evans, J. Population studies on 14 Gilbert Syndrome. J. Med. Genet. 1975;12: 152-15 156. 16 17 Bailey, A., Robinson, D. and Dawson, A.M. Does 18 Gilbert's disease? Lancet 1977; 1: 931-933. 19 20 Reaven, G.M. Syndrome X: 6 years later. J. 21 Intern. Med. 1994; 236: 13-22. 22 23 Ebner. T., Remmel, R.P. and Burchell, B. Human 24 20. bilirubin UDP-glucuronosyltransferase catalyses 25 the glucuronidation of ethinylestradiol. Molec. 26 Pharmacol. 1993; 43: 649-654. 27 28 Edwards, A., Hammond, H.A., Jin, L., Caskey, C.T. 29 and Chakraborty, R. Genetic variation at five 30 trimeric and tetrameric tandem repeat loci in four 31 human population groups. Genomics 1992; 12: 241-

77T #	T146
CLA	LMD

Use of a test for detecting the genetic basis of 3 1. 4 Gilbert's Syndrome in a method to improve the efficacy of drug trials, the method comprising 5 6 screening samples from potential participants for 7 the basis of Gilbert's Syndrome and eliminating or 8 including potential participants in a drug trial 9 in the knowledge of them possessing or not 10 possessing the genetic basis of Gilbert's 11 Syndrome.

12 13

2. Use of a test as claimed in claim 1 wherein the method comprise the steps of:

14 15

16 a) taking a sample from each potential 17 participant in a drug trial,

18

19 b) screening the samples for the genetic basis 20 of Gilbert's Syndrome,

21 22

C) identifying participants having the genetic basis of Gilbert's Syndrome, and

23 24

> 25 d) proceeding with drugs trials in the knowledge 26 of participants possessing or not possessing 27 the genetic basis of Gilbert's Syndrome.

28

29 3 Use of a test as claimed in claim 1 or 2 wherein 30 the sample is chosen from blood, buccal smear or 31 any other sample containing DNA from the potential 32 participants.

33

34 4. Use of a test as claimed in any of the preceding 35 claims further comprising the step of eliminating 36 participants having the genetic basis of Gilbert's

6104070701;#45

25

1		Syndrome from a drugs trial.
2		
3	5.	Use of a test as claimed in any of claims 1 to 3
4		where in the method comprises the further step of
5		selecting only participants having genetic basis
6		for Gilbert's Syndrome for a drugs trial.
7		
8	6.	Use of a test as claimed in any of claims 1 to 3
9		further comprising the step of interpreting the
10		results of the drugs trial in the knowledge that
11		certain participants have Gilbert's Syndrome.
12		
13	7.	Use of a test as claimed in any of the preceding
14		claims wherein the method comprises the steps of:
15		
16		a) isolating DNA from each sample,
17		
18		b) amplifying the DNA inner region indicating
19		the genetic basis for Gilbert's Syndrome,
20	•	
21		c) isolating amplified DNA fragments, and
22		
23		<ul> <li>d) identifying individuals having the genetic</li> </ul>
24		basis of Gilbert's Syndrome.
25		
26	8.	Use of a test as claimed in any of the preceding
27		claims wherein the DNA is amplified using the
28		polymerase chain reaction (PCR) using a
29		radioactively labelled pair of nucleotide primers.
30		
31	10.	Use of a test as claimed in any of claims 7 to 9
32		wherein the DNA region indicating the genetic
33		basis of Gilbert's Syndrome is the gene encoding
34		UDP-glucuronosyltransferase (UGT).
35		
36	11.	Use of a test as claimed in any of claims 7 to 10

6104070701;#46


26

MURGITROYD & CO. -

1		wherein the DNA to be amplified is in an upstream
2		promoter region of the UGT 1*1 exon 1.
3		
4	12.	Use of a test as claimed in any of claims 7 to 11
5		wherein the DNA to be amplified includes the
6		regions between -35 and -55 nucleotides at the 5'
7		end of UGT 1*1 exon.
8		
9	13.	A kit for screening individuals participation in
10		drug trials, the kit comprising primers for
11		amplifying DNA in the region of the genome
12		indicating the genetic basis of Gilbert's
13		Syndrome.
14		
15	14.	Primers for use of a test as claimed in any of the
16		preceding claims including primer pairs, AB or CD
17		as follows:
18		
19		A/B(A,5'-AAGTGAACTCCCTGCTACCTT-3',
20		B,5'-CCACTGGGATCAACAGTATCT-3') or
21		C/D (C,5'-GTCACGTGACACAGTCAAAC-3';
22		D 5'-TTTGCTCCTGCCAGAGGTT-3').

PCT/GB97/00577

1/4







Fre 1b

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

PCT/GPOTIONET





I, II, III - generations in family \*= genetic and biochemical data accident

□ ○ homozygotes for the (TA), TAA allele

female

heterozygotes for the (TA), TAA and (TA), TAA alleles

(13) = total serum bilirubin

(18-25) = elevated total serum bilirubin


SUBSTITUTE SHEET (RULE 26)

gray gives of the result gives from those of the stand that the stand the south gives gives gives the stand of the stand the s

API -611 GTGAGTCTGGCTCACCTCATGGCGCGTGGCTCGTGTGGTGGGCTCTGCTGCAGCCTCCAA Spl -54] GACACCACACTGTGCTGGACTCAATAAATAATGTTGGACGAAGGAATGAAACACATGATA -491 CAAGTGAGCAGCAGTACCGGGGGAGCTGTGGAGTGGGCACTCTTACAGGTTTCCATGGC -431 GAAAGOGGGGGGACAGTTGTGTTCTTTTCTTTCTAAAAGGCTTTCTAAAAAGCCTTCTGT -371 TTAATTTCTGGAAAAGAAGCCTAACTTGTTCACTACATAGTCGTCCTTCTTCCTCTCTGG AP3 -311 TAACACTTGTTGGTCTGTGGAAATACTAATITAATGGATCCTGAGGTTCTGGAAGTACTT -191 GCCTATTAAGAAACCTAATAAAGCTCCACCTTCTTTATCTCTGAAAGTGAACTCCCTGCT -131 ACCTTTGTGGACTGACAGCTTTTTATAGTCACGTGACACAGTCAAACATTAALLIO

-71 ATCGATTGGTTTTTGCCATATATATATATATAAGTAGGAGAGGGCGAACCTCTGGCAGGA

-11 GCAAAGGCGCCATGGCTGTG





SUBSTITUTE SHEET (RULE 26)

# Declaration and Power of Attorney For Patent Application English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

DRUG TRIAL ASSAY SYSTEM,

he specification of which	is stacked boroto uni	occ tha tallawing	DOY IS CHECKED.
tha coacitication at Walce	as anachen nerem um	1622 1116 10110MILIA	
HE Specification of which	15 attaciled fields will		

was filed on 03 March 1997 as

United States Application Number or PCT International Application Number PCT/GB97/00577 and was amended on 03 April 1998 and 01 September 1998 (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Prior Foreign	Appl	ication	S	)
---------------	------	---------	---	---

Priority Not Claimed

9604480.5

GB

01 March 1996 (01.03.96)

(Number)

(Country)

(Day/Month/Year Filed)

9605598.3

GB

16 March 1996 (16.03.96)

(Number)

(Country)

(Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

	Application Number)	(	Filing Date)	(Status - paten	ted, pending, abandoned)	
-	(Application Number)	. (	Filing Date)	(Status - paten	ted, pending, abandoned)	1
l	POWER OF ATTC agent(s) to prosect connected therewith	ute this applic	named inventor, cation and transact	I hereby appoin all business in	it the following atto the Patent and Tra	rney(s) and/or demark Office
	Allan Ratner R Andrew L. Ney R Kenneth N. Nigon R Kevin R. Casey R Benjamin E. Leace R	eg.No. 23,031 eg.No. 19,717 eg.No. 20,300 eg.No. 31,549 eg.No. 32,117 eg.No. 33,412 eg.No. 24,842	Lawrence E. Ashery Robert L. Andersen Christopher R. Lewis Louis W. Beardell, Jr. Rocco L. Adornato Jacques L. Etkowicz Eric A. Dichter	Reg.No. 34,515 Reg.No. 25,771 Reg.No. 36,201 Reg.No. 40,506 Reg.No. 40,480 Reg.No. 41,738 Reg.No. 41,708	Mark J. Marcelli Joshua L. Cohen Christopher J. Dervishian Jack J. Jankovitz	Reg.No. 36,593 Reg.No. 38,040 Reg.No. 42,480 Reg.No. 42,690
3,44	Address all correspo <u>Ratner &amp; Prestia, l</u> Address all telephor	Suite 301, On	<u>llan Ratner</u> e Westlakes, Berwyr an Ratner at (610) 4	ı <u>, P.O. Box 980, \</u> 07-0700.	/alley Forge, PA 194	<u>82-0980</u>
W. and the Sub the time R tl B	statements made of were made with the by fine or imprison	on informatior e knowledge iment. or botl	n and belief are bel that willful false n, under Section 10	ieved to be true; statements and 001 of Title 18 o	n knowledge are true and further that the the like so made f the United States ation or any patent is	ese statements are punishable Code and that
նում կորե Պուու Գոսն 16° 18° ուսոն Կոյե հուր Պուու II 18	statements made of were made with the by fine or imprison such willful false stated with the such will false stated with the such with	on information e knowledge iment, or both atements may inventor (given rown) / N/S / Soft freet, Tayport, Fif	n and belief are bel that willful false n, under Section 10	ieved to be true; statements and 201 of Title 18 of idity of the applicate CHELL, Brian	and further that the the like so made f the United States	ese statements are punishable Code and that
մորդ կորի կորո ԳոսԲ Ա" լա որով Գուն մրոի Կուս և Ա	statements made of were made with the by fine or imprison such willful false stated with the such willful false stated will name of sole or first Inventor's signature Residence 8 Dougall Stated Citizenship GB  Post Office Address 8 E	on information e knowledge ment, or both atements may inventor (given rown) with the country of	n and belief are belthat willful false in, under Section 10 y jeopardize the validation and particular family name) BUR for DD6 9 JB GREAT BRI	ieved to be true; statements and 001 of Title 18 of idity of the applicant of the statements.  CHELL, Brian  LU  TAIN	and further that the the like so made for the United States ation or any patent is	ese statements are punishable Code and that

# ļub 170

### Declaration and Power of Attorney For Patent Application **English Language Déclaration**

As a below named inventor, I	hereby	declare	that:
------------------------------	--------	---------	-------

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

DRUG TRIAL ASSAY SYSTEM,

ייייייי	J		<u> </u>			_	-	
	:E4:	مام نطیر کم	in attached	horoto	unlace th	e following	hoy is i	checked:
tne si	pecification	Of Which	is attached	LIGI CIO	UI IICOO II I	e lollowing		or io or to a.

was filed on 03 March 1997 as

United States Application Number or PCT International Application Number PCT/GB97/00577 and was amended on 03 April 1998 and 01 September 1998 (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed: Priority Not Claimed

Prior Foreign Application(s)

9604480.5

GB

01 March 1996 (01.03.96)

(Number)

(Country)

(Day/Month/Year Filed)

9605598.3

GB

16 March 1996 (16.03.96)

(Number)

(Country)

(Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

- 31	÷	Sand British Sall Bull	will to	11111111	3	in the		collect it there there are not constraint	:22	1	Mr. Same	1
ı			::									
			,				-			:		
							 25,000	The same	75 35		13,44.63	

(Application Number)		(Filing Date)	(Status - pater	nted, pending, abandoned)	
(Application Number)		(Filing Date)	(Status - pater	nted, pending, abandoned)	
	ecute this app			nt the following atto the Patent and Tra	
Paul F. Prestia Allan Ratner Andrew L. Ney Kenneth N. Nigon Kevin R. Casey Benjamin E. Leace James C. Simmons	Reg.No. 23,031 Reg.No. 19,717 Reg.No. 20,300 Reg.No. 31,549 Reg.No. 32,117 Reg.No. 33,412 Reg.No. 24,842	Lawrence E. Ashery Robert L. Andersen Christopher R. Lewis Louis W. Beardell, Jr. Rocco L. Adornato Jacques L. Etkowicz Eric A. Dichter	Reg.No. 34,515 Reg.No. 25,771 Reg.No. 36,201 Reg.No. 40,506 Reg.No. 40,480 Reg.No. 41,738 Reg.No. 41,708	Mark J. Marcelli Joshua L. Cohen Christopher J. Dervishian Jack J. Jankovitz	Reg.No. 36,593 Reg.No. 38,040 Reg.No. 42,480 Reg.No. 42,690
Address all teleph I hereby declar statements mad- were made with by fine or impris	a, Suite 301, One calls to: All see that all see on information the knowledge conment, or bo	ne Westlakes, Berwyr lan Ratner at (610) 4 tatements made he on and belief are beli e that willful false th, under Section 10	o7-0700.  erein of my ow ieved to be true statements and only of Title 18 o	Valley Forge, PA 194  n knowledge are true; and further that the like so made a first the United States eation or any patent is	ue and that all ese statements are punishable Code and that
Full name of sole or t	first inventor (given	name, family name) BURG	CHELL, Brian		
Inventor's signature	N/S			Date	
Residence <u>8 Dougal</u> Citizenship <u>GB</u> Post Office Address	Street, Tayport, F  8 Dougall Street	ife DD6 9 JB GREAT BRI 9 JB GREAT BRITAIN	<u>TAIN</u>		
Full name of second	joint inventor, if an	y (given name, family nam	e)		
Second Inventor's sig Residence Citizenship Post Office Address				Date	
Additional inv	entors are being na	ımed on separately numbe	ered sheets attached	hereto.	